Long-standing COVID-19 infection outcomes like cognitive & functional, and acute neurological complexities are less discussed, presented, and documented substantially.
It includes breathing & gastrointestinal difficulties, sleep disturbances, frequent headaches, anxiety episodes, depressed feelings, attention impairment & loss of memory.
In inappropriately handled long-lasting hospitalized patients warning consequences of chronic stage causes mental challenges & “brain fog”.
Long COVID care demands the development of patient-centered preventive measures, rehabilitation techniques & clinical management procedures. Simultaneously detailed analysis and understanding of the prevalence, risk factors, and pathophysiology of brain fog is crucial.
In post-acute sequelae, COVID-19 patients, structural & functional abnormalities of frontal, temporal, and limbic areas develop.
Olfactory network structural changes including prefrontal structures, corpus callosum and insula involvement, temporal lobe, basal ganglia, brainstem, and cerebellum are the most reported.
The cognitive disturbance duration depends on the severity of cognitive damage.
Brain fog is a descriptive terminology & is explained by the patients as a diverse bunch of intellectual function-related complications comprising trouble in thinking, remembering, and reasoning that interferes with daily functioning and instigates neuropsychological dysfunctions.
As per the World Health Organization (WHO), brain fog is defined as an informal term for a common complaint of intellectual functions among patients with post-acute COVID-19. Impairment of cognitive function, confusion, short-term memory loss, dizziness, and inability to concentrate come under brain fog.
It is a common characteristic in healing or recovering patients affecting their higher cognitive or “executive” function.
Brain fog requires serious attention from medical practitioners in employing its instructive & protective procedures.
Virus-induced long-standing & neurodegeneration cognitive impairment denotes the hippocampal distribution of microglial activation, systemic inflammation & sepsis.
Severe acute intensive care patients of COVID-19 develop hypoxia, vascular nerve cell injury & endothelial dysfunction associated with microvascular damage. Concomitantly immunological dysregulation, chronic inflammation & peripheral organ dysfunction occur. Cerebral white matter becomes vulnerable to ischaemic injury, cerebral hypoperfusion, amyloid-beta rapid accumulation, and TAR DNA binding protein-43 pathology.
There are also chances of systemic inflammatory injury & abnormalities, blood-brain barrier permeability increase & disturbance in tight junction proteins associated with brain parenchyma.
Cognition controlling the hippocampus, temporal lobe, and thalamus gets affected by thrombotic and inflammatory cascade leading to capillary occlusion, and ischemia.
Suitable intervention strategies, scientific community-based future studies & trials can reduce long-lasting COVID-19-related cognitive diminishing symptoms & their effects.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
2.
Prostate Cancer Treatment Associated With Long-Term Complications
3.
Unraveling the role of exercise in cancer suppression
4.
Parkinson patient's gait is restored by a spinal cord stimulator.
5.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
1.
The Unseen Danger of Anal Cancer: How to Protect Yourself
2.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
3.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
4.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
5.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation